iSpecimen Inc. — fact timeline

iSpecimen Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 29, 2026, iSpecimen Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Capital Market”). As reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company had stockholders’ equity of $814,038. Nasdaq noted that, as of May 29, 2026, the Company doe”

iSpecimen Inc. shareholders approved Approval of the iSpecimen Inc. 2025 Stock Incentive Plan at the 2026-05-29 meeting.

“Proposal No. 3: Approval of the iSpecimen Inc. 2025 Stock Incentive Plan The third proposal was the approval of the iSpecimen Inc. 2025 Stock Incentive Plan. The vote on the proposal was as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE 461,073 186,740 64,979 2,266,267 Proposal No. 3 was approved by a majority of the votes cast.”

iSpecimen Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-29 meeting.

“Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm The second proposal was the ratification of the appointment of Bush & Associates CPA LLC as the Company’s independent registered public accounting firm for the year ending December 31, 2025. The vote on the proposal was as follows: FOR AGAINST ABSTAIN 2,424,420 155,256 399,383 Proposal No. 2 was approved by a majority of the votes cast.”

iSpecimen Inc. shareholders approved Election of One Class I Director at the 2026-05-29 meeting.

“Proposal No. 1: Election of One Class I Director The first proposal was the election of one (1) Class I director to serve for a three-year term that expires at the 2028 Annual Meeting of Stockholders, or until the election and qualification of their respective successor in office, subject to their earlier death, resignation or removal. The vote on the proposal was as follows: Name of Nominee FOR WITHHELD BROKER NON-VOTE Arphing (Tommy) Lee 562,361 150,431 2,266,267 The nominee was elected.”

iSpecimen Inc. entered into Securities Purchase Agreement with certain accredited investors valued at aggregate gross proceeds of approximately $2.5 million (effective 2026-05-08).

“On May 8, 2026, iSpecimen Inc., a Delaware corporation (Nasdaq: ISPC) (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell 488,281 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock” or “Shares”), at a purchase price of $5.12 per Share.”

iSpecimen Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“May 12, 2026, the Company received a letter from Nasdaq (the “Compliance Letter”) notifying the Company that the Staff has determined that for the last 10 consecutive business days, from April 28, 2026 to May 11, 2026, t”

iSpecimen Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for the prior 30 consecutive business days. On May 12, 2026”

iSpecimen Inc.: Fifth Amended and Restated Certificate of Incorporation filed to effect 1-for-40 reverse stock split and ratify prior 1:20 reverse stock split (effective 2026-04-29).

“On April 29, 2026, iSpecimen Inc. (the “Company”) filed a Fifth Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware, which, among other things, effectuated a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share, at a ratio of 1-for-40 (the “Reverse Stock Split”).”

iSpecimen Inc.: Filed an Amended Certificate of Designation for Series C Convertible Non-Voting Preferred Stock that adjusts Conversion Price and Floor Price proportionately upon reverse stock splits or similar transactions (effective 2026-01-16).

“On January 16, 2026, the Company filed an Amended Certificate of Designations, Preferences and Rights of the Series C Convertible Non-Voting Preferred Stock (the “ Amended Certificate of Designation ”) with the Secretary of State of the State of Delaware.”

iSpecimen Inc. entered into Consulting Agreement with IR Agency LLC valued at aggregate cash fee of $2,000,000 (effective 2025-12-31).

“On December 31, 2025, the Company entered into a Consulting Agreement (the “Consulting Agreement”) with IR Agency LLC (the “Consultant”), pursuant to which the Consultant agreed to provide marketing, advertising and investor communications services to the Company.”

iSpecimen Inc. issued 6,875 shares of Series C Preferred Stock of preferred stock to certain accredited investors for aggregate purchase price of $5.5 million.

““Floor Price”). Pursuant to the Purchase Agreement, on December 31, 2025, the Company issued and sold 6,875 shares of Series C Preferred Stock for an aggregate purchase price of $5.5 million at the closing (the “Closing”). In connection with the Purchase Agreement, the Company also entered into a Registration Rights Agreement with the Investors (the “Registration”

iSpecimen Inc.: Company filed a Certificate of Designation establishing the Series C Convertible Non-Voting Preferred Stock (effective 2025-12-30).

“On December 30, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Non-Voting Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, establishing the rights, preferences, privileges and limitations of such Series C Preferred Stock.”

iSpecimen Inc. entered into Placement Agent Agreement with E.F. Hutton & Co. valued at Placement Agent agreed to act as the Company’s exclusive placement agent in connection with the Offe (effective 2025-12-30).

“In addition, in connection with the Offering, the Company entered into a Placement Agent Agreement, dated December 30, 2025 (the “Placement Agent Agreement”), with E.F. Hutton & Co. (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s exclusive placement agent in connection with the Offering, subject to the terms and conditions set forth therein.”

iSpecimen Inc. entered into Registration Rights Agreement with the Investors valued at Company agreed to provide certain registration rights with respect to the resale of the Conversion S (effective 2025-12-30).

“In connection with the Purchase Agreement, the Company also entered into a Registration Rights Agreement with the Investors (the “Registration Rights Agreement”), pursuant to which the Company agreed to provide certain registration rights with respect to the resale of the Conversion Shares, and agreed to file an initial registration statement within certain time periods as set forth in the Registration Rights Agreement to register the Conversion Shares.”

iSpecimen Inc. entered into Securities Purchase Agreement with certain accredited investors valued at 6,875 shares of Series C Convertible Non-Voting Preferred Stock having a stated value of $1,000 per (effective 2025-12-30).

“On December 30, 2025, iSpecimen Inc., a Delaware corporation (Nasdaq: ISPC) (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which the Company agreed to sell, and the Investors agreed to purchase, 6,875 shares of the Company’s newly-designated Series C Convertible Non-Voting Preferred Stock, par value $0.0001 per share (the “Series C Preferred Stock”), having a stated value of $1,000 per share, at a purchase price of $800 per share.”

iSpecimen Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 19, 2025, iSpecimen Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s common stock had been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for the prior 30 consecutive business days. As a result, the Company is no longer in compliance with the Minimum Bid Price Requirement. The Notice has no”

iSpecimen Inc.: Amended bylaws to reduce the quorum requirement for shareholder meetings from a majority to 34% of voting power (effective 2025-07-09).

“On July 9, 2025, iSpecimen Inc. (the “Company”) amended its Second Amended and Restated Bylaws (the “Bylaws”) to modify the quorum requirement for shareholder meetings. The amendment reduced the quorum threshold from a majority of the voting power of the Company’s outstanding shares entitled to vote at a meeting to 34% of such voting power.”

Anthony Lau was appointed as Director at iSpecimen Inc..

“On June 20, 2025, the Board appointed Mr. Anthony Lau as a member of the Board, effective immediately, to fill one of the resulting vacancies.”

John L. Brooks III resigned as Director at iSpecimen Inc..

“On June 18, 2025, Richard J. Paolone and John L. Brooks III each resigned from the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”), effective immediately.”

Richard J. Paolone resigned as Chairman of the Board at iSpecimen Inc..

“On June 18, 2025, Richard J. Paolone and John L. Brooks III each resigned from the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”), effective immediately.”

iSpecimen Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“June 4, 2025, iSpecimen Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it no longer complies with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market. As reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2025, the Company had stockholders’ equity of $1,668,513. Nasdaq further noted that the Company does not currently meet the alternative continued listing crite”

iSpecimen Inc. engaged Bush & Associates CPA LLC as its auditor.

“On March 10, 2025, following the approval of the Audit Committee of the Company’s Board of Directors, the Company appointed Bush & Associates CPA LLC (“Bush & Associates”) as its new independent registered public accounting firm to serve as the Company’s auditor for the fiscal year ending December 31, 2024.”

Wolf & Company, P.C. resigned as auditor of iSpecimen Inc..

“On March 7, 2025, iSpecimen Inc. (the “Company”) was notified that Wolf & Company, P.C. (“Wolf & Company”) resigned as the Company’s independent registered public accounting firm, effective immediately.”

Richard Paolone was appointed as Chair of the Board at iSpecimen Inc..

“Additionally, the Board appointed Mr. Richard Paolone as Chair of the Board, replacing Ms. Field in this role.”

Siyun Yang was appointed as Director at iSpecimen Inc..

“Ms. Siyun Yang was appointed as an independent director to fill the resulting vacancy, effective immediately.”

Katharyn Field was appointed as President at iSpecimen Inc..

“On February 19, 2025, the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”) appointed Ms. Katharyn Field as President of the Company, effective immediately. In connection with her appointment, Ms. Field resigned as a member of the Board”

Tracy Curley resigned as Director at iSpecimen Inc..

“Ms. Curley resigned as a member of the Board of Directors (the “Board”), due to differences between Ms. Curley and the Board regarding the future direction of the Company.”

Tracy Curley departed as Chief Executive Officer, Chief Financial Officer and Treasurer at iSpecimen Inc..

“On November 8, 2024, iSpecimen Inc. (the “Company”) and Tracy Curley mutually agreed to end Ms. Curley’s employment as Chief Executive Officer, Chief Financial Officer and Treasurer of the Company.”

Katherine (Katie) Field was appointed as Chairperson at iSpecimen Inc..

“effective upon Closing on September 25, 2024, Richard Paolone, Avtar Dhaliwal and Katherine (Katie) Field were each appointed to serve on the Board as a Class I director, a Class II director and a Class III director of the Company, respectively, with Ms. Field appointed as the chairperson of the Board”

Avtar Dhaliwal was appointed as Director at iSpecimen Inc..

“effective upon Closing on September 25, 2024, Richard Paolone, Avtar Dhaliwal and Katherine (Katie) Field were each appointed to serve on the Board”

Richard Paolone was appointed as Director at iSpecimen Inc..

“effective upon Closing on September 25, 2024, Richard Paolone, Avtar Dhaliwal and Katherine (Katie) Field were each appointed to serve on the Board”

Elizabeth A. Graham resigned as Director at iSpecimen Inc..

“Elizabeth A. Graham, as a member and the chairperson of the Board, effective upon Closing”

Theresa Mock resigned as Director at iSpecimen Inc..

“The Company received letters of resignation from each of Steven Gullans and Theresa Mock, each as a member of the Board”

Steven Gullans resigned as Director at iSpecimen Inc..

“The Company received letters of resignation from each of Steven Gullans and Theresa Mock, each as a member of the Board”

Andrew L. Ross resigned as director at iSpecimen Inc..

“On July 17, 2024, iSpecimen Inc. (the “Company”) received a written notice from Andrew L. Ross that he will be resigning as a director of the Company, effective July 25, 2024.”

Benjamin Bielak resigned as Chief Information Officer and Secretary at iSpecimen Inc..

“On July 5, 2024, iSpecimen Inc. (the “Company”) received written notice from Benjamin Bielak that he will be resigning as Chief Information Officer and Secretary of the Company, effective July 15, 2024.”

iSpecimen Inc. reported for the quarter ended March 31, 2024 results: revenue approximately $2.29 million, net income approximately $2.90 million, EPS ($0.32) per share.

“For the quarter ended March 31, 2024, revenue was approximately $2.29 million, compared to approximately $2.95 million for the quarter ended March 31, 2023.”

Elizabeth A. Graham was appointed as Class III Director at iSpecimen Inc..

“On March 21, 2024, the Board, at a Special Meeting of the Board of Directors, appointed Elizabeth A. Graham as a Class III director of the Company and a member of the nominating and corporate governance committee of the Board.”

iSpecimen Inc. reported year ended December 31, 2023 results: net income net loss was approximately $11.10 million, EPS (1.23) per share.

“For the year ended December 31, 2023, the net loss was approximately $11.10 million, or (1.23) per share, compared to a net loss of approximately $10.2 million, or $(1.16) per share, for the same period the prior year.”

iSpecimen Inc. reported twelve-month period ended December 31, 2023 results: revenue $9.93 million, net income $11.10 million net loss, EPS (1.23) per share.

“For the year ended December 31, 2023, revenue was approximately $9.93 million, compared to approximately $10.40 million for the year ended December 31, 2022.”

iSpecimen Inc. entered into At the Market Offering Agreement with Rodman & Renshaw LLC valued at $1,500,000 (effective 2024-03-05).

“On March 5, 2024, iSpecimen Inc., a Delaware corporation (the “Company”), entered into an At the Market Offering Agreement (the “ATM Agreement”) with Rodman & Renshaw LLC as agent (the “Sales Agent”) pursuant to which the Company may issue and sell shares of its common stock, $0.0001 par value per share, having an aggregate offering price of up to $1,500,000 (the “Shares”), from time to time through the Sales Agent (the “Offering”).”

iSpecimen Inc. terminated Warrant Repurchase and Termination Agreements with Warrant Holders valued at $0.04 per share issuable upon full exercise of warrants (effective 2024-02-13).

“On February 13, 2024, iSpecimen Inc. (the “ Company ”) entered into certain warrant repurchase and termination agreements (the “ Repurchase Agreement ”) with certain holders (each, the “ Warrant Holder ”) of warrants (the “ Warrants ”) with an issuance date of December 1, 2021 at an exercise price of $13.00 per share for the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), in connection with an aggregate of up to 1,312,500 shares of Common Stock exercisable under the Warrants.”

Joseph J. Basile resigned as Director at iSpecimen Inc..

“On December 15, 2023, iSpecimen Inc. (the “Company”) received a letter of resignation from Joseph J. Basile to resign as a member of the Board of Directors of the Company (the “Board”), effective December 31, 2023.”

iSpecimen Inc. reported the three and nine month periods ended September 30, 2023 results: revenue $2.8 million for the three-month period ended September 30, 2023, net income $2.1 million, or $(0.23) per share, EPS $(0.23) per share.

“iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and nine month periods ended September 30, 2023.”

iSpecimen Inc. reported the quarter ended September 30, 2023 results: revenue $2.6 to $2.8 million.

“The Company expects third quarter 2023 revenue to be between $2.6 to $2.8 million, representing an increase of between 60% to 70% from second quarter 2023 revenue of $1.63 million.”

iSpecimen Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“October 9, 2023, iSpecimen Inc., a Delaware corporation (the “Company”) received a deficiency notice from The Nasdaq Stock Market (“Nasdaq”) informing the Company that its common stock, par value $0.0001 per share (the “Common Stock”), fails to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the Common Stock for the 30 consecutive business days prior to the date of the notice from Nasdaq. Nasdaq’s notice has no immediate effect on the listing of the Common Stock on The Nasd”

iSpecimen Inc. reported the six months ended June 30, 2023 results: revenue approximately $4.6 million, net income approximately $5.9 million, EPS $(0.66) per share.

“both our top and bottom-line results,” concluded Curley. Q2 2023 Financial Results & Recent Operational Highlights · Revenue of $1.63 million for the three month period and $4.6 million for the six month period of 2023 compared to $2.34 million for the three month period and $4.9 million for the six month period of 2022. · Unique supplier organizations under”

iSpecimen Inc. reported second quarter of 2023 results: revenue approximately $1.63 million, net income approximately $3.5 million, EPS $(0.39) per share.

“supplier and customer base, we expect to build both our top and bottom-line results,” concluded Curley. Q2 2023 Financial Results & Recent Operational Highlights · Revenue of $1.63 million for the three month period and $4.6 million for the six month period of 2023 compared to $2.34 million for the three month period and $4.9 million for the six month period of”

Christopher Ianelli resigned as director at iSpecimen Inc..

“On July 7, 2023, the Board of Directors of iSpecimen Inc. (the “Company”) received a letter of resignation from Christopher Ianelli to resign as a director of the Company, effective immediately.”

iSpecimen Inc. shareholders approved Ratification of appointment of Wolf & Company, P.C. as independent registered public accounting firm for the year ending December 31, 2023.

“Proposal No. 5 was approved by a majority of the votes cast.”